Tissue Regenix Takeover Rumours (TRX)

Tissue Regenix Chart

Tissue Regenix Takeover Price

Tissue Regenix Takeover Forum Posts

24-01-2020
100% likelihood of recapitalisation with I'd guess disaggregated likelihoods of... 12.5% takeover 25% disposals/divestment 50% placing 50% rights issue 100% cash management/cash generation
20-01-2020
That is still highly unlikely to provide any return to shareholders because by definition it's a "liquidation" (ie the company is effectively insolvent so its Board throws in the towel voluntarily before its creditors pull the plug through one or other legal means). The only solution (other than a rights issue or financial restructuring) would be a trade sale or even a takeover, but in TRX's current situation that wouldn't offer much return to shareholders. In short, the company desperately requires working capital.... within 2 months.
14-01-2020
With the share price so low. What is the percentage chance of a takeover here?
08-01-2020
Amazing ground covered by this company, FDA approved products and more to come. Record revenue growth, expanding globally. Massive demand that the company is now addressing with double shifts, new facilities. Takeover target for sure. Break even this year possible..forced down to 1p levels. 1p levels are laughable.
17-12-2019
Bob i kind of agree its unlike many aim company’s. It certainly has potential but im not looking to wait for years we need an rns asap. Also i doubt it will be taken over soon like some ppl think takeover .. probably a year or two. We need an rns asap
12-12-2019
They never said placing it could be anything... my takeover implication is based on their broker saying as such.....You seem a bit derampy sunshine sold out have and trying to buy back in cheaper?
Yes but nothing to suggest a takeover is imminent .. this has been said a year ago.. rns suggests or implies placing by March
10-12-2019
It’s a takeover at 5 quid a share, but their waiting till Christmas to tell us as it’s out present for being good boys and girls.
06-12-2019
Another snippet Companies with products addressing similar needs have fetched valuations of US$500-700mln. Tissue Regenix has several product areas and so will get several shots at goal, Jefferies adds.Based on historical takeover valuations, all of these areas combined could be worth "north of US$1.5bn or about 10 times the current share price in a break-up and take-out scenario".
https://www.proactiveinvestors.co.uk/companies/news/53891/tissue-regenixs-takeover-value-may-eventually-top-us1bn-suggests-broker-63919.html
27-11-2019
A proposed takeover at 29p
8p year high am i right in thinking a takeover would have to be at or over the 52week high paid? They are talking sbout this on lse
There has been talks of a takeover for some time. I’m sure someone said back when it was 7p there was a mention. So at this price a TO would be a steal. But then wouldn’t BOD require holders approval, unless they can negotiate with out best interests. Who knows, somthing going down and I’ll sit tight and watch the games get played.
22-11-2019
Worst case scenario for me is a takeover. Even if that does happen it’s a win win :)
21-11-2019
Dont forget TRX were a takeover target at 7p not long ago.......The Jefferies analysts also said: “We believe the combined technology platforms would strengthen the opportunities for strategic partnerships, as evidenced by the recent deals.”They added: “We also view TRX as an attractive takeover target for its broad innovation platform that addresses needs in various segments.”Jefferies forecasts Tissue Regenix reporting group sales of £18mln in full-year 2019, up 53.9% year-on-year, advancing to £26mln in 2020 and £37mln in 2021.The broker reiterated a ‘buy’ rating on Tissue Regenix shares with a price target of 10p per share.The stock currently trades at 7p a share, giving Tissue Regenix a market capitalisation of around £82mln.
I do think some things else is going on here though. Kristen replaces the CFO but doesn’t have the title, instead is the Group Finance Director, and doesn’t sit in the board. Am I being too imaginative to suggest there is talks of a takeover?
19-11-2019
#TRX gone from 1m sales in 2016 to 15m sales in 2019, if growth like this continues it should be a huge takeover target for a bigger player, their products are gaining market traction and just now started European distribution, 2020 huge year for the company
#TRX gone from 1m sales in 2016 to 15m sales in 2019, if growth like this continues it should be a huge takeover target for a bigger player, their products are gaining market traction and just now started European distribution, 2020 huge year for the company
desperate rampers They do not know when they pumped and been dumped on. There possibly 600-700m still in profit. TheAppleFreak19 Nov '19 - 08:43 - 3384 of 3386 Trx takeover targetToday 08:10 We also view TRX as an attractive takeover target for its broad innovation platform that addresses needs in various segments.â€￾ Jefferies forecasts Tissue Regenix reporting group sales of ?18mln in full-year 2019, up 53.9% year-on-year, advancing to ?26mln in 2020 and ?37mln in 2021.
Trx takeover targetToday 08:10We also view TRX as an attractive takeover target for its broad innovation platform that addresses needs in various segments.”Jefferies forecasts Tissue Regenix reporting group sales of ?18mln in full-year 2019, up 53.9% year-on-year, advancing to ?26mln in 2020 and ?37mln in 2021.
Trx takeover targetToday 08:10 We also view TRX as an attractive takeover target for its broad innovation platform that addresses needs in various segments.â€￾ Jefferies forecasts Tissue Regenix reporting group sales of £18mln in full-year 2019, up 53.9% year-on-year, advancing to £26mln in 2020 and £37mln in 2021.
Trx takeover targetToday 08:10 We also view TRX as an attractive takeover target for its broad innovation platform that addresses needs in various segments.â€￾ Jefferies forecasts Tissue Regenix reporting group sales of £18mln in full-year 2019, up 53.9% year-on-year, advancing to £26mln in 2020 and £37mln in 2021.
Trx takeover targetToday 08:10 We also view TRX as an attractive takeover target for its broad innovation platform that addresses needs in various segments.â€￾ Jefferies forecasts Tissue Regenix reporting group sales of £18mln in full-year 2019, up 53.9% year-on-year, advancing to £26mln in 2020 and £37mln in 2021.
Trx takeover targetToday 08:10 We also view TRX as an attractive takeover target for its broad innovation platform that addresses needs in various segments.â€￾ Jefferies forecasts Tissue Regenix reporting group sales of £18mln in full-year 2019, up 53.9% year-on-year, advancing to £26mln in 2020 and £37mln in 2021.
Trx takeover targetToday 08:10 We also view TRX as an attractive takeover target for its broad innovation platform that addresses needs in various segments.â€￾ Jefferies forecasts Tissue Regenix reporting group sales of £18mln in full-year 2019, up 53.9% year-on-year, advancing to £26mln in 2020 and £37mln in 2021.
Trx takeover targetToday 08:10 We also view TRX as an attractive takeover target for its broad innovation platform that addresses needs in various segments.â€￾ Jefferies forecasts Tissue Regenix reporting group sales of £18mln in full-year 2019, up 53.9% year-on-year, advancing to £26mln in 2020 and £37mln in 2021.
Trx takeover targetToday 08:10 We also view TRX as an attractive takeover target for its broad innovation platform that addresses needs in various segments.â€￾ Jefferies forecasts Tissue Regenix reporting group sales of £18mln in full-year 2019, up 53.9% year-on-year, advancing to £26mln in 2020 and £37mln in 2021.
Trx takeover targetToday 08:10 We also view TRX as an attractive takeover target for its broad innovation platform that addresses needs in various segments.â€￾ Jefferies forecasts Tissue Regenix reporting group sales of £18mln in full-year 2019, up 53.9% year-on-year, advancing to £26mln in 2020 and £37mln in 2021.
Trx takeover targetToday 08:10 We also view TRX as an attractive takeover target for its broad innovation platform that addresses needs in various segments.â€￾ Jefferies forecasts Tissue Regenix reporting group sales of £18mln in full-year 2019, up 53.9% year-on-year, advancing to £26mln in 2020 and £37mln in 2021.
Trx takeover targetToday 08:10 We also view TRX as an attractive takeover target for its broad innovation platform that addresses needs in various segments.â€￾ Jefferies forecasts Tissue Regenix reporting group sales of £18mln in full-year 2019, up 53.9% year-on-year, advancing to £26mln in 2020 and £37mln in 2021.
13-11-2019
Very true..if this was an attractive takeover target at 7p..yes 7p. Then what this it make it now at 1p...x7 more attractive!!
Taken more #TRX 0.75p on shake. If You want some now is your chance on this dip. This is a takeover target for sure. If it was identified as a bid target at 7p in February then at 0.70p in November 1/10th of the price it’s a Total No Brainer IMO #TRx Forget 2.5 much more
What order is it?- TR1- Agreement on ONE performance Covenant - Takeover bid
12-11-2019
1.5p on sellers out!!! 3p on loan facility. 4p on more contracts 10p on takeover
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200218 22:36:47